

2021 IMPACT REPORT



Lung
Foundation
Australia

Supporting patients and carers



3,222

health-related enquiries to our Information and Support Centre.

902,944 people connected with resources, support services and programs via our website.



849 people connected to peer support.

99 information resources developed for patients.

4 Consumer Advisory Committees.

Supporting best-practice patient care and support



3,000+ healthcare professional registrations for learning sessions to educate and upskill the workforce.

14,199 engaged health professionals.



20

clinical committees and networks.



225,400+ views on our **2** clinical toolkits.

Increasing research investment

\$9.5 million raised or pledged to our Hope Research Fund.



\$1,964,814 invested to support advances in research.

11 Hope Research Fund partnership grants awarded.



28 collaborations with research institutions and partnerships.

Driving lung health policy changes

76 government submissions to advocate for prevention, early detection, treatment, support and care, including 28 patient-voice led submissions to the PBAC.

41 newly trained consumer advocates.

200+ meetings with consumer advocates, Members of Parliament and Senators.

Raising the profile of lung health

6,114 national, earned media stories about lung health reached

357 million+ people.



24,484 people accessed our online Lung Health Checklist.

10.2 million+ Australians reached through our public health campaigns.



2020 PRIME Awards:

- NGO of the Year.
- Best use of Data and Insights for Lung Cancer Search and Rescue.



2021 Mumbrella CommsCon Award:

- Best use of Research and Insights for Lung Cancer Search and Rescue.



*Research to us means the world.
It gives families such as ours and all
families caring for someone with
lung disease hope.*

- Shaun, Eve's Father



Our 2020/2021 impact	2
Michelle's story	4
The facts	5
Welcome	6
About us	7
Supporting patients and carers	8
Driving lung health policy changes	9
Increasing research investment	10
Supporting best-practice patient care	12
Fundraising and community champions	13
Raising the profile of lung health	13
Our Board	14
Our people	15
Corporate partners and supporters	16
Financials	17
How you can help	20

Owing to a change of financial year to 30 June,
this report reflects activity for the period
1 July 2020 to 30 June 2021.

Michelle's story

“My hope for the future is that more research and support will be put in place to achieve early diagnosis, increased medical care, education and support for those diagnosed and their families. This can assist all in adapting to living with the disease and not being defined by it.”

Michelle is a loving mother of three adult children. The family have always led a very active and sporty lifestyle so when day-to-day activities became a struggle, Michelle knew something wasn't right. From a young age, she experienced health issues including chronic bronchitis, asthma, pneumonia and re-occurring chest infections. In her mid 40's, the diagnosis of tuberculosis and bronchiectasis was a devastating blow.

“The chronic and incurable diagnosis was bittersweet. Having a greater understanding of my condition and how to manage it – through exercise, medical help, an action plan and support from my family and friends – means that I can ensure it has the least impact on my day-to-day life as possible.

Lung Foundation Australia has been an amazing source of information and support to me and my family. I was motivated to join the Bronchiectasis Consumer Advisory Committee in 2020 as a way to assist, educate and support others living with lung disease, and their families. My son Max lives with a form of chronic arthritis, and he has been involved in sharing his voice and experiences which inspired and motivated me further to get involved. I then took on the position as Chair of the National Consumer Committee with the hope that my experiences and passion can make a difference and shed light through greater awareness.

It's the contributions and support of the community that can help us move forward through research, earlier diagnosis and management. Together let's reduce the prevalence of lung disease in Australia, increase awareness, and support those living with a lung disease to live stronger, better lives.”

Read more of Michelle's story at lungfoundation.com.au/michelles-story.




The National Consumer Committee Advisory Council consists of people living with lung disease and lung cancer who provide advice to Lung Foundation Australia on a variety of issues and topics across information and support, research, advocacy, fundraising, and community awareness.

Click here to find out more and meet our members.



Front cover: Michelle (pictured here), living with bronchiectasis, her son Max and husband Phillip (pictured here).



Lung disease and lung cancer is **Australia's second** leading cause of **death**.



Two thirds of people

living with a lung condition feel isolated and suffer from a lack of confidence.

Stigma is a **major barrier** to accessing research, treatment and support.



Lung disease accounts for **9% of total disease burden** in Australia, yet it only receives **2% of research investment**.

There is much to be proud of when we look back on Lung Foundation Australia's impact over the last 18 months. For 31 years we have been the trusted consumer peak body working towards a future free from lung disease and lung cancer. We have been at the forefront of lung research funding, patient support, policy development and awareness campaigns to give hope to the 1 in 3 Australians personally impacted by lung disease or lung cancer.

COVID-19, a respiratory virus, has challenged the world and changed nearly every facet of our lives. The 2020 bushfires and COVID-19 pandemic continue to place enormous pressure on our resources but everyone at Lung Foundation Australia has worked hard to keep the community and our supporters informed, connected and safe. With your help we have emerged stronger, more connected and more focused on our Mission, to champion programs so Australians with lung disease and lung cancer can live their best life.

The Australian and several State and Territory Governments continue to recognise our leadership and impact. Pleasingly, several new multi-year programs to tackle the National Strategic Action Plan for Lung Conditions have been funded, in particular the Specialist Lung Cancer Nurse pilot programs. This project will be transformative for people impacted by lung cancer.

People with lung disease and lung cancer face increased health risks from COVID-19 and Lung Foundation Australia continues to be a trusted source of information and support. Through the hard work of staff and countless volunteers, innovation has thrived as we adapt to the uncertainty created by the pandemic. Lung Foundation Australia has continued to build its profile, and despite the loss of nearly all community-based events, the organisation has achieved its growth targets. Just as importantly, Lung Foundation Australia will continue to seek solutions to meet the needs of patients, families and carers, for as long as COVID-19 continues to challenge us.

Lung Foundation Australia's oldest partnership with the Thoracic Society of Australia and New Zealand (TSANZ) has significantly strengthened over the last two years as our organisations collaborated on two key projects in Occupational Lung Disease and the Primary Health Care Lung Learning Competency and Education Framework. In total, Lung Foundation Australia will provide \$725,000 in funding over three years to achieve the projects' outcomes. Lung Foundation Australia looks forward to working with the TSANZ Board, CEO and team to connect their members with resources and services to support their patients.

Our thanks to the thousands of healthcare professionals, researchers and consumers for your gifts of time, expertise and experience, voice and generous donations.

To our Board, staff, Subcommittees, Expert Advisory Groups, partners and benefactors, thank you.



Professor Christine Jenkins AM
Chairperson



Mark Brooke
Chief Executive Officer



Lung Foundation Australia is the only charity and leading peak body of its kind in Australia that funds life-changing research and delivers support services that give hope to Australians. Since 1990, we have been working to ensure lung health is a priority for all by promoting lung health and early diagnosis, advocating for policy change and research investment, raising awareness about the symptoms and prevalence of lung disease and championing equitable access to treatment and care.

Our Vision

Lung Foundation Australia enables life-saving lung health and lung cancer research, and champions programs so that Australians with lung disease and lung cancer can live their best life.

Our Mission

By 2030, Lung Foundation Australia will be recognised as one of the world’s most innovative and effective lung health charities and a fearless leader of lung health and lung cancer policy, programs and research.

Our Values

Bold | be proactive and take risks that achieve our Mission.

Entrepreneurial | be focused on outcomes.

Fair | be equitable and work in the interests of all our stakeholders, particularly patients and their carers.

Agile | create positive change.

Innovative | be inventive to achieve our Mission.

Respectful | be honest and work hard every day in every way – we are funded by the community, they should expect nothing less.



Acknowledgement of Country

Lung Foundation Australia acknowledges Australia’s First Nations People and pay our respect to Aboriginal and Torres Strait Islander Elders, past, present and emerging. We do so in a spirit of reconciliation recognising that Aboriginal and Torres Strait Islander people across Australia are significantly overrepresented in lung disease and lung cancer. We commit to partnering with communities to address this and Close the Gap.

Artist: Jordan Lovegrove, Dreamtime Creative

2021 Objective

The go-to resource for lung health and lung disease.

2021 Targets

15% of those diagnosed with lung diseases 'are actively engaged' with Lung Foundation Australia.

Progress

Achieved, on target and continuing as a priority.

Supporting Australians impacted by lung disease and lung cancer is our core mission. Our life-changing programs and services empower people to access the care and support they deserve. Throughout this year our Information and Support Centre team have provided 3,222 people with education and guidance to help them live their best life.

Our Consumer Engagement Strategy allows consumers, carers and families to play an active role in our planning, implementation and evolution. Through their lived experience, our four Consumer Advisory Committees help inform the development of our resources, services and programs.

Prioritising mental wellbeing

Our Lived Experience research found that feelings of isolation, frustration, and fear are common for people living with a lung condition, and the emotional and mental impact takes a significant toll. This year we launched Mind Matters – an information and resource hub co-designed with consumers and experts. The hub is designed to provide consumers, and their families and carers, with tools and strategies to prioritise and care for their mental wellbeing. Visit the Mind Matters hub at lungfoundation.com.au/MindMatters.

Telephone nurse support

More than 600 people living with lung cancer and chronic lung conditions were connected with information and guidance through our free nurse-led telephone support service. Our expert nurses support people to navigate the often-challenging health system and arm them with the tools to live well with their condition. Data shows people who participate in the program report significant improvements in self-management strategies. Action Plan ownership more than doubled from the first to final call, uptake of pulmonary exercise

programs increased, and reported symptoms and psychological burden reduced.

Peer support connections

Peer support offers invaluable connection and understanding for people living with lung disease and lung cancer, their families, and carers. Our peer support program has expanded significantly with 849 people connected in with one of our groups which span across 10 conditions. These groups meet face-to-face, online, and over the telephone as well through one-on-one meetings.

“Being with others who understand and connecting is so important. We are not islands. We need the support of other people.”
– Jan, Peer Support Leader.

Support through the pandemic

In 2020 we formed a COVID-19 Expert Working Group to collaborate on the development of an internationally recognised digital information hub to meet the needs of our community through the pandemic. In 2021 we aided the establishment of a support group for Australian's living with long-COVID and will continue working with leading experts to develop resources and information for this ever-growing community.



Nicole, Jilian and Amanda, Lung Foundation Australia's nurses.



2021 Objective

A leading advocate for lung health.

2021 Targets

Government increases the relative priority it places on lung disease.

Progress

Achieved, tracking ahead of target and continuing as a very high priority.

Department of Health National Strategic Action Plan for Lung Conditions

The Action Plan outlines key recommendations to reduce the burden of lung conditions, improve lung health and ensure every Australian impacted by lung disease or lung cancer has the same access to care and support as those with other chronic diseases. This year, government funding was secured to deliver on the following recommendations.

Tackle Occupational Lung Disease (OLD)

In response to Australia’s growing silicosis epidemic, we developed a suite of resources including an online questionnaire to help workers identify their risk of developing OLD due to exposure to hazardous agents and a national online directory of information and support services for employers, employees and people living with OLD.

Chronic cough education and awareness

The update of the Cough in Children and Adults: Diagnosis and Assessment (CICADA) Position Statement is underway. This will be used to inform a suite of resources aimed at improving diagnosis and treatment of patients with chronic cough, particularly in high-risk populations including Aboriginal and Torres Strait Islander children.

Drive immunisation uptake for high-risk populations

Working with a specialist agency we designed and delivered a targeted campaign for Aboriginal and Torres Strait Islander communities who are at an increased risk of experiencing severe cases of respiratory infection. The campaign raised awareness of the importance of vaccination against respiratory infections including influenza, pneumonia and COVID-19.

Upskill health professionals

The Federal Government announced \$1.4 million in funding to design and deliver a competency-based lung health education and training framework for primary healthcare professionals, helping this workforce identify symptoms earlier, facilitate specialist referral more quickly and achieve better outcomes for patients. We are working collaboratively with the Department of Health, TSANZ and Asthma Australia to deliver this project.

Implement lung cancer screening

Funding to support the early scoping of the national targeted lung cancer screening program was committed to in the 2021/2022 Federal Budget. We support this program, led by Cancer Australia, as it is a critical step to improving early diagnosis and outcomes for Australians living with lung cancer, with an estimated 12,000 lives to be saved in the first 10 years.

Vaping and Young People

A ground-breaking Curtin University study into flavoured e-liquids, supported by Lung Foundation Australia, Minderoo Foundation and Scottish Masonic Charitable Foundation WA, uncovered major concerns about the dangers and health risks these products pose. The research found 100% of the e-liquids were inaccurately labelled and 1 in 5 contained nicotine. Our consensus statement, developed with key stakeholders, calls for government action including stronger regulations, monitoring and enforcement. In response, we developed a suite of resources to educate Australians, specifically young people, about the risks. These resources will be used as part of an awareness campaign launching in August 2021, supported by nib foundation People’s Choice grant.

2021 Objective

Driving trends and direction of research.

A valued hub for all stakeholders.

2021 Targets

Lung Foundation Australia's annual support for research is \$5 million per annum.

Strong collaboration with Thoracic Society of Australia and New Zealand.

Progress

Partially achieved, tracking towards target.

Achieved and continuing as a high priority.

Lung Foundation Australia's research program encompasses a multi-million-dollar grants and awards program, internationally renowned registries, and impactful research partnerships. This program relies on the support of our corporate partners and generosity of community supporters through events such as Shine a Light on Lung Cancer.

Hope Research Fund

This year we were proud to launch the Hope Research Fund, our 10-year commitment to driving life-changing lung disease and lung

cancer research. This Fund forms part of our mission to become one of the nation's leading investors in lung health research, with the goal to raise \$50 million by 2030 to support ground-breaking discoveries in prevention, diagnosis, treatment and cure.

The Fund launched in April 2021 with over \$9 million invested through major gifts and bequests.

"To me, a gift to Lung Foundation Australia in my Will is a gift to future generations of Australians, to ensure that they can live the lives that they want - in longer health and with greater support."

- Caroline, wife of Bill who lived with Chronic Obstructive Pulmonary Disease (COPD).

Professor Kwun Fong, The Prince Charles Hospital, Queensland. Researcher, Lung Foundation Australia's Lung Cancer Clinical Advisory Committee Chair, and award recipient. Professor Fong featured in our Hope Research Fund television commercial.



Data collection driving research

Our registries collect real-world patient data which helps researchers to improve our understanding of lung diseases.

- The Australian Bronchiectasis Registry is the only registry worldwide to hold longitudinal data on both adult and paediatric patients with bronchiectasis. It was established to facilitate epidemiological research in bronchiectasis, but in the long-term aims to drive improvements in quality of care for patients.
- After 10 years of successful operation, the Australian Idiopathic Pulmonary Fibrosis (IPF) Registry is being finalised. Recognised as an international leader, the Registry has had over 860 participants. The data has informed 19 publications in peer reviewed journals and 66 papers presented at national and international conferences. The data will remain available for approved projects to allow research to continue. The registry provided the foundation for the development of the Centre of Research Excellence in Pulmonary Fibrosis.

- The Australasian Interstitial Lung Disease Registry will continue to drive greater research impact with a broader focus beyond IPF. More than 20 sites are participating across both Australia and New Zealand, with over 2,000 registry participants.

Connecting patients with clinical trials

Proudly supported by Lung Foundation Australia, the Pulmonary Fibrosis Australasian Clinical Trials Network (PACT) unites dedicated and passionate leading clinicians and researchers to search for cutting-edge treatments that will improve quality of life and outcomes for people living with Pulmonary Fibrosis (PF). This year PACT endorsed and listed seven new clinical trials, with more trials underway in Australasia than ever before. The PACT Consumer Advisory Group was formed to assist with research, providing invaluable consumer input for researchers at all stages of the research process. The outlook for PF is now completely different compared to only a few years ago.

Investing in the best and brightest researchers

Our awards and grants program supports talented researchers, like Dr Afaf Abed, to harness their skills and make real and meaningful advancements in the prevention, diagnosis and treatment of lung disease and lung cancer. Dr Abed's project, which was supported by the Ellen Yates Memorial Grant-in-Aid for Lung Cancer Research, has discovered that certain genes can be used as a biomarker to help predict whether patients with non-small cell lung cancer will respond to immunotherapy. This is critical to individualise treatment and tackle the disease as quickly as possible. Meet Dr Abed and our other inspiring researchers, at lungfoundation.com.au/researchers.



“My hope for the future is to find a cure for cancer with treatment personalisation. While this might not be achievable in near future, it is not impossible with ongoing research.”

– Dr Afaf Abed.
Linear Clinical
Research – Oncology,
Western Australia.

2021 Objective

Guided by evidence and best-practice.

A successful collaborator.

2021 Targets

25% increase in health professional engagement with Lung Foundation Australia.

Progress

Achieved, on target and continuing as a very high priority.

Achieved, strengthening and continuing as a priority.

Underpinned by evidence-based guidelines and informed directly by the needs and lived experience of our consumer community, our clinical programs are designed to translate research into practice for Australia’s lung health workforce and support improvements to the quality of care provided to people living with lung disease and lung cancer.

We are grateful to our national network of clinicians and health professionals who generously donated almost 1,000 hours of their time, through the COVID-19 pandemic, to support us in the design and implementation of evidence-based guidelines, clinical resources, community of practice forums and education. Our programs are highly regarded by lung health professionals with reach across Australia and to over 22 countries internationally.

Clinical guidelines

In partnership with TSNAZ, we led the implementation of two internationally recognised guidelines for COPD and pulmonary rehabilitation. Our clinical guidelines provide world-class and evidence-based recommendations that support thousands of health professionals to deliver best-practice care. Through targeted advocacy and partnership with Health Departments, we are working toward our goal of achieving increased uptake and application of clinical guidelines through development of national clinical care standards and quality improvement programs.

Accredited eLearning in lung cancer

In partnership with Cancer Australia and multidisciplinary lung cancer experts, we developed an accredited eLearning course

designed to upskill and support primary care health professionals in their application of the clinical resource, [Investigating symptoms of lung cancer: a guide for all health professionals](#). This free course, launching in September 2021, aims to help facilitate early identification and rapid referral of people with suspected lung cancer, with the goal of improving health and wellbeing outcomes.

“Being prepared with the knowledge of an evidence-based, step-wise approach to investigation and referral of lung cancer may help save a life.”



- Dr Kerry Hancock, GP and Lung Foundation Australia Primary Care Clinical Advisory Committee Chair.

Lung Learning

Building on the success of our established education program for health professionals, we developed the [Lung Learning virtual education series](#) focusing on differential diagnosis and treatment of lung conditions. The series, presented by recognised clinical experts, is designed to increase awareness of common symptoms of lung conditions and current recommendations for investigation and referral.

Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF)

The ANZ-LCNF is Australia’s largest community of practice for thoracic oncology nurses with 500+ members. Through extensive engagement with the broader ANZ-LCNF membership, we developed a 3-year strategy, setting a clear course for future workforce development. Read the new 3-year strategic plan at anzlcnf.com.au/strategy.

2021 Objective

Driving trends and direction of research.

2021 Targets

Lung Foundation Australia’s annual support for research is \$5 million per annum.

Progress

Partially achieved, tracking towards target - \$10 million raised and invested in the Hope Research Fund.



Rebecca Marsh (left) and her late mum, Annette (right).

Former 7News presenter Rebecca Marsh (pictured above), became a Lung Foundation Australia Ambassador when her mother, Annette, was diagnosed with Stage 4 lung cancer. The impact of stigma and lack of funding inspired Rebecca to fundraise through Challenge 30 and Shine a Light on Lung Cancer. Annette sadly passed away in April 2021. We thank Rebecca and her family for their incredible ongoing support.


partners and incredibly generous gifts in Wills. Lung Foundation Australia and our community gratefully acknowledge and thank our supporters.

 **\$6.5 million** raised.

This year over \$6.5 million was raised by nearly 4,400 supporters to help deliver on our mission. Our supporters include donors, community fundraisers, trusts and foundations, corporate

Challenge 30

Since launching in 2020, Challenge 30 has raised over \$90,000. The virtual community fundraising campaign raises money for lung disease and lung cancer research, advocacy and support services. Spanning 300 hours, this event encourages participants to raise money by undertaking a personal challenge.

 [Click here to find out more.](#)

Raising the profile of lung health

Recent national research shows just 1 in 5 Australians have discussed their lung health with a health professional in the past 12 months. This is despite as many as 1 in 3 reporting symptoms that could indicate lung disease or lung cancer. Lung Foundation Australia’s two national symptom awareness campaigns educated Australians to recognise persistent or changed symptoms, leading to almost 25,000 people completing our interactive Lung Health Checklist.

We also campaigned for Australians to work together to safeguard against viruses, and to ensure those at-risk took steps to protect themselves and their loved ones against vaccine-preventable diseases like influenza, pneumococcal pneumonia and COVID-19. As a result 37,000+ people accessed information and resources about protecting their respiratory health.

To learn more, visit lunghealth.lungfoundation.com.au.

The Lung Foundation Australia Board consists of ten directors who volunteer their expertise and time to help improve lung health and reduce the impact of lung disease for all Australians.



Professor Christine Jenkins AM

Chair (Non-Executive), MB BS (Hons II), MD, FRACP
 Chair of the Remuneration Sub-committee. Member of the Finance, Audit, Risk Management Sub-committee. Member of the Investment Advisory Sub-committee.



Mr Andrew Churchill

Deputy Chair (Director), FCA, MAICD
 Member of the Remuneration Sub-committee. Chair of the Finance, Audit, Risk Management Sub-committee. Chair of the Investment Advisory Sub-committee. Patient/Carer representative.



Ms Kathleen Cummings

Director, Grad.Dip in Management (CSU), GAICD
 Member of the Finance, Audit, Risk Management Sub-committee. Patient/Carer representative.



Ms Melissa Le Mesurier

Director, GAICD, B.Arts (Politics and Journalism)
 Member of Development Sub-committee. Patient/Carer representative.



Doctor David Michail

Director, MB BS, FRACP
 Member of the Finance, Audit, Risk Management Sub-committee. Member of the Investment Advisory Sub-committee.



Associate Professor Lucy Morgan

Director, B.Med PhD, FRACP
 Chair of the Australasian Bronchiectasis Consortium. Clinical lead for Australian Bronchiectasis Registry.



Professor Martin Phillips

Director, BSc, MB BS, MRCP, FRACP
 Member of The Australian Lung Foundation Inc. National Council since August 2001. Founding Board Member of Lung Foundation Australia.



Professor Sarath Ranganathan

Director, MCChB, MRCP, FRCPCH, PhD
 Member of COVID-19 Expert Working Group. Member of Young Lungs Advisory Group.



Ms Angela Ratcliffe


Director, GAICD, B.Bus
 Member of Development Sub-committee. Patient/Carer representative.



Professor Paul Reynolds

Director, MB BS PhD, MD, FRACP, FThorSoc
 Investigator - Centre of Research Excellence in Pulmonary Fibrosis.

For a comprehensive overview of Lung Foundation Australia's governance, strategic, risk and financial frameworks please review our Audited Financial Statement on our website.

 [Click here to read more about our Board Members.](#)




Lung Foundation Australia staff at a Shine a Light on Lung Cancer event.



5 new
positions



Cultural competence
training for all staff



Giving our staff a voice

As part of our corporate objective of keeping our team well, Lung Foundation Australia’s Board commissioned two independent surveys to provide insight and feedback on the progress, passion and wellbeing of staff. The positive feedback from staff resulted in Lung Foundation Australia winning the Voice Project’s Workplace of the Year Award.

The top performing areas included our team believing in the purpose and work done by Lung Foundation Australia, clarity and belief in the values of the organisation and that there is a strong focus on achieving positive results.

Supporting staff wellbeing

Lung Foundation Australia offers an Employee Assist Program to all staff and their immediate families and our consumer advocates and committee members. This anonymous and independent service is part of our commitment to staff self-care, mental health and wellbeing. In 2021, we will introduce paid mental health leave to ensure the wellbeing of our staff is of highest priority.

189 consumer volunteers and
284 clinical volunteers contributed
\$750,900+ in unpaid support.

2021 Objective

Annual community fundraising revenue growth.

2021 Targets

\$1.5 million per annum.

Progress

Achieved, ahead of target and continuing as a very high priority.

Government

Australian Government
Department of Health
Cancer Australia
Department of Jobs,
Precincts and Regions
National Health and
Medical Research Council
NSW Ministry of Health
Queensland Health
Queensland Stronger
Communities Fund

Estates

Andrew John Harrison
Antonia Rasen
Beverley Mcilwain
Catherine Elizabeth
Davies
Eric Phillips
John Farrell
Judith Wilson
Margaret Mayes
Mavis Walker
Ray and Irene Chambers
Velma Dawn Brady

Major Donors 5k+

Barry and Elizabeth Frost
Bernadette Eaton
Brent and Vicki Emmett
Dr Diana Cox (dec)
Ho Hau Tak
Janice Butterworth
Joan Whyte
Lynn Yager
Mira and Garry Cummins
Nathalie Quinlivan
Pamela Lumb
Rabia Manchanda
Sebastiana Carmusciano
Tony and Gai Wales

Corporate Donors and Community Partners

BHP Billiton
De Pasquale Group of
Companies
Deutsche Börse Group

Komatsu Australia
LARF (Lungs and
Respiratory Friends)
Lions Club of Lugarno Inc
Mylan
Viacom
Vocus Communications
Volvo Group Australia

Grants, Trusts and Foundations

Ann Helene Toakley
Charitable Endowment
managed by Perpetual
Limited
Coffs Harbour Pink Silks
Perpetual Trust
Dick and Pip Smith
Foundation
Dimmick Charitable Trust
Elaine Walters Foundation
Everhard Industries
Foundation
Gambling Community
Benefit Fund
Lionel and Yvonne
Spencer Trust managed
by Perpetual Limited
Lung Ambition Alliance
Minderoo Foundation
Nelson Alexander
Charitable Foundation
nib foundation
Queensland Community
Foundation
Robert Fergusson Family
Foundation
Scobie and Claire
Mackinnon Trust
Scottish Masonic
Charitable Foundation
Slater and Gordon
Lawyers
Woodend Foundation

Community Fundraising Partners

Anita McGrath and Alison
Bolton
Bruce Serisier
Cassy Morris Foundation

Danah Cummins
Declase Family
Evangeline Lim Lung
Cancer Foundation
Fiona Telfer
Jacob Lynch
Morris Family
Rebecca Marsh
Riordan Family
Trail to Triumph –
Ultramarathon for
Mesothelioma

Corporate Partners

A. Menarini Australia
Amgen Australia
AstraZeneca Australia
Avalyn Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Australia
Chiesi Australia
Cipla
Galapagos NV
GSK Australia
Insmid
Janssen-Cilag
Medical Developments
International
Merck Sharp & Dohme
Mylan
Novartis
Novotech
Pfizer Australia
Roche Australia
Seqirus
Takeda
Viatrix Australia
Zambon

Research Collaborations, Universities, and Institutions

Curtin University
Edith Cowan University
La Trobe University
Melbourne Health
Menzies Research

Institute Tasmania
Menzies School of Health
Research
Monash University
Newcastle University
Queensland University of
Technology (QUT)
RMIT University
Sir Charles Gairdner
Hospital
The Garvan Institute for
Medical Research
University of Newcastle
University of South
Australia
University of Sydney
University of Tasmania
University of Technology
Sydney
University of Western
Australia
Walter and Eliza Hall
Institute of Medical
Research

Research and Health Partnerships

Australasian
Bronchiectasis Consortia
Three Lakes Foundation
USA
Better Breathing
Foundation
Cochrane Airways
Centre of Research
Excellence in Pulmonary
Fibrosis
Centre of Research
Excellence -Treatable
Traits
Thoracic Society of
Australia and New
Zealand
Lung Health Alliance
Asthma Australia
Australasian Interstitial
Lung Disease Registry
Pulmonary Fibrosis
Australasian Clinical Trials
Network

I am delighted on behalf of the Board's Finance, Audit and Risk Management (FARM) Subcommittee and the Investment Advisory Subcommittee to present the Lung Foundation Australia's financial performance as at 30 June 2021. Please note the report represents six months of operations due to a change of our financial year end to 30 June.

For the second year the Foundation's balance sheet has strengthened with Equity at \$7,621,286, an increase of \$2,286,276 (42.85%) over last year.

The improved financial position reflected in the balance sheet was achieved due to an operating surplus of \$2,286,276 for the six months. This is compared to the full year result in 2020 of \$2,962,272 (a variance of \$675,996 or 22.82%). As the Foundation continues to adapt to the uncertainties created by the COVID-19 pandemic, and the associated disruptions to the organisation's fundraising program and services more broadly, a further \$2,943,299 was invested into the Hope Research Fund.

The Foundation is committed to growing the lung health research corpus to \$50 million by 2030 and has achieved 19.84% of this ambitious target. To aid this ambitious project, an Investment Advisory Subcommittee was formed to advise the Board and ensure the maximum amount of investment income is flowing to research activities. With a strong pipeline of bequests and major gifts, the Board approved \$950,000 in lung disease and lung cancer research in round one of grant making.

Income has strengthened with several new Commonwealth and State Government grants secured to expand services and increase impact. Equally the FARM Subcommittee has carefully monitored our administration and fundraising expenses (10% and 11% respectively) to ensure funds for programs, services, lung health awareness and research were maximised.


The Subcommittee has also updated the Foundation's Risk Management Plan to reflect the ever-evolving impact of COVID-19. The Board has approved the creation of the position of Senior Manager - People and Culture, as our headcount continues to grow, and to ensure our policies, procedures and practices are best practice.

I acknowledge the members of both the FARM and Investment Advisory Subcommittees for their significant contribution of time and expertise and thank each one, together with our donors and supporters for a successful year in review.


Andrew Churchill

Chairperson


FARM and Investment Advisory Subcommittees



- Health Programs (26%)
- Research (26%)
- Awareness/Advocacy (27%)
- Fundraising (11%)
- Admin, Governance, Compliance (10%)



- COPD (25%)
- Lung Cancer (29%)
- Pulmonary Fibrosis (31%)
- Rare Lung Diseases (15%)



- Corporate (20%)
- Donations (15%)
- Bequests (39%)
- Government (9%)
- Other Revenue (2%)
- Investment Income (13%)
- Sales (2%)
- Events (0%)

Lung Foundation Australia statement of profit or loss and other comprehensive income

For the six months ended 30 June 2021

	6 months to 30 June 2021 [\$]	Restated Year to 31 December 2020 [\$]
Continuing operations		
Grants - Government	577,905	1,239,424
Grants - other sources	531,828	393,831
Sponsorships	581,007	1,855,405
Donations	927,186	1,148,820
Bequests	2,444,575	2,332,470
Events	-	137,875
Net change in fair value of financial assets classified at fair value through profit or loss	612,485	231,782
Revenue from specifically designated funds	107,750	191,939
Other income	391,513	1,518,524
Total revenue and other income from continuing operations	6,174,249	9,050,070
Research expenses	(908,740)	(1,403,443)
Programs and services expenses	(440,790)	(997,402)
Employee Expenses	(1,572,318)	(2,838,641)
Fundraising expenses	(300,697)	(158,583)
Marketing expenses	(227,269)	(214,485)
Other expenses	(450,289)	(503,283)
Surplus / (deficit) from continuing operations before finance income	2,274,146	2,934,233
Finance income	12,130	28,039
Net surplus / (deficit)	2,286,276	2,962,272
Other comprehensive income		
Items that may be reclassified subsequently to profit or loss:		
Total comprehensive income / (loss)	2,286,276	2,962,272
Net surplus / (deficit) for the year is attributable to:		
Members	2,286,276	2,962,272
	2,286,276	2,962,272
Total comprehensive income / (loss) for the year is attributable to:		
Members	2,286,276	2,962,272
	2,286,276	2,962,272

Lung Foundation Australia statement of financial position

As at 30 June 2021

	6 months to 30 June 2021 [\$]	Restated Year to 31 December 2020 [\$]
Current assets		
Cash and cash equivalents	870,365	1,334,516
Receivables	262,675	379,650
Other current assets	239,643	148,624
Financial assets - Hope Research Fund	-	-
Financial assets - Company	781,833	1,161,008
Total current assets	2,154,516	3,023,798
Non-current assets		
Financial assets - Hope Research Fund	9,136,275	5,813,801
Financial assets - Company	76,756	76,756
Property, plant and equipment	132,580	153,621
Right of Use Asset	522,804	569,676
Intangible assets	-	-
Total non-current assets	9,868,415	6,613,854
Total assets	12,022,931	9,637,652
Current liabilities		
Payables	131,610	222,018
Income in advance	2,683,181	2,426,641

Contract liability	785,425	838,425
Lease liabilities	204,998	214,422
Employee benefits	184,325	139,127
Total current liabilities	3,989,539	3,840,633
Non-current liabilities		
Payables	-	-
Lease liabilities	368,427	403,829
Employee benefits	43,679	58,180
Total non-current liabilities	412,106	462,009
Total liabilities	4,401,645	4,302,642
Net assets	7,621,286	5,335,010
Equity		
Retained earnings	7,621,286	5,335,010
Total equity	7,621,286	5,335,010

Lung Foundation Australia statement of cash flows

For the six months ended 30 June 2021

6 months to
30 June 2021
[\$]

Restated Year
to 31 December
2020 [\$]

Cash flows from operating activities		
Receipts from operating activities from government	577,905	1,239,454
Receipts from operating activities (except government grants)	6,255,190	8,615,912
Payments for operating activities	(4,949,679)	(6,287,296)
Dividends received	71,784	130,974
Interest received	9,023	29,313
Interest paid	(17,315)	(39,863)
Net cash flows from operating activities	1,946,908	3,688,494
Cash flows from investing activities		
Proceeds from term deposits	-	10,929
Acquisition of securities and equities	(4,982,542)	(6,730,640)
Proceeds from sale of securities and equities	2,728,343	2,837,242
Acquisition of plant and equipment	(9,497)	(23,077)
Acquisition of intangible assets	-	-
Net cash flows used in investing activities	(2,263,696)	(3,905,546)
Cash flows from financing activities		
Payment of finance lease liabilities (principal)	(147,363)	(224,841)
Net cash flows used in financing activities	(147,363)	(224,841)
Net increase/(decrease) in cash and cash equivalents held	(464,151)	(441,893)
Cash and cash equivalents at the beginning of the financial year	1,334,516	1,776,409
Cash and cash equivalents at the end of the financial year	870,365	1,334,516

Lung Foundation Australia statement of changes in equity

For the six months ended 30 June 2021

	Financial Assets Reserve [\$]	Retained Earnings [\$]	Total Equity [\$]
Balance at 1 January 2020	62,952	2,309,786	2,372,738
Adjustment on change in accounting policy	(62,952)	62,952	-
Balance at 1 January 2020 - Restated	-	2,372,738	2,372,738
Net surplus / deficit for year - Restated	-	2,962,272	2,962,272
Other comprehensive income for the year - Restated	-	-	-
Balance at 31 December 2020 - Restated	-	5,335,010	5,335,010
Net surplus / deficit for six months	-	2,286,276	2,286,276
Other comprehensive income for six months	-	-	-
Balance at 30 June 2021	-	7,621,286	7,621,286

How you can help



Leave a gift in your Will

A gift in your Will is a gift of hope to future generations. A hope that one day a cure can be found and Australians living with lung disease and lung cancer can live their best life. Every gift, no matter the size, makes a powerful difference to the future of millions of Australians living with devastating lung conditions.



Give a regular gift

Regular giving is a simple and effective way to help make a real difference to continuing awareness, education, support and research into lung disease and lung cancer. Your regular monthly donation helps Lung Foundation Australia plan for the future, providing security through ongoing funding, as well as saving on administration costs - so every dollar goes even further.



Philanthropy and partnerships

We are proud to partner with philanthropists, companies, trusts and foundations whose values are aligned with ours. We believe that all partnerships should have impact and we work closely with our corporate and philanthropic partners to make sure their investment continues to deliver on their objectives.



Become a member

Lung Foundation Australia membership is not required to access any information or services offered by the organisation. However, your membership will provide us with much needed ongoing support, and in return you will join a community of health professionals, researchers and patients all striving to improve care for the seven million Australians impacted by lung disease and lung cancer.



Level 2, 11 Finchley Street MILTON QLD 4064

PO Box 1949 MILTON QLD 4064

enquiries@lungfoundation.com.au

lungfoundation.com.au

Free call 1800 654 301



Voice Project Workplace
of the Year



This report was
printed on EcoStar
100% recycled paper.